SuppreMol GmbH, which is developing therapies for autoimmune diseases, has appointed Michael Tansey as chief development officer overseeing preclinical and clinical development of its Fc-gamma receptor product family. Dr Tansey, who qualified in medicine in 1973, was previously chief medical officer at NovaCardia Inc (now Merck & Co Inc) and at La Jolla Pharmaceutical Company. During his career Dr Tansey has been involved in the clinical development and approval of more than 15 small molecule and biological drugs.
SuppreMol announced the appointment on 10 September 2013.
Copyright 2013 Evernow Publishing Ltd